Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea

被引：10

作者：

Kattamis, A

Lagona, E

Orfanou, I

Psichou, F

Ladis, V

Kanavakis, E

Metaxotou-Mavrommati, A

Kattamis, C

机构：

[1] Univ Athens, Sch Med, Dept Pediat 1, GR-11527 Athens, Greece

[2] Univ Athens, Sch Med, Dept Med Genet, GR-11527 Athens, Greece

来源：

PEDIATRIC HEMATOLOGY AND ONCOLOGY | 2004年 / 21卷 / 04期

关键词：

adverse events; hydroxyurea; sickle; thalassemia;

D O I：

10.1080/08880010490440473

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The authors studied the long-term clinical and hematological response to hydroxyurea (HU) therapy in young patients, with either S/beta-thalassemia (beta(thal) ) (8 patients) or SS (6 patients). All patients with S/beta(thal) responded well to treatment. Longitudinal evaluation of Hb, HbF, and MCV showed a significant increase compared to baseline levels, but the pattern of HbF changes varied among patients. Changes in HbF and Hb correlated well with baseline HbF. Favorable clinical responses, as documented by decline in hospitalization days for vasoocclusive crisis and transfused units of packed red blood cells, were also noted. During treatment, 1 patient was diagnosed with Hodgkin's lymphoma and 2 patients developed bilateral avascular necrosis of the femoral head. HU seems to be effective in a high proportion of young patients with sickle cell disease and in particular with S/beta(thal) , but cannot eliminate occurrence of serious adverse events.

引用

页码：335 / 342

页数：8

共 17 条

[11] SICKLE-CELL DISEASE AS A CAUSE OF OSTEONECROSIS OF THE FEMORAL-HEAD [J].

MILNER, PF ;

KRAUS, AP ;

SEBES, JI ;

SLEEPER, LA ;

DUKES, KA ;

EMBURY, SH ;

BELLEVUE, R ;

KOSHY, M ;

MOOHR, JW ;

SMITH, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (21) :1476-1481

[12] Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea [J].

Moschovi, M ;

Psychou, F ;

Menegas, D ;

Tsangaris, GT ;

Tzortzatou-Stathopoulou, F ;

Nikolaidou, P .

PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2001, 18 (06) :371-376

[13] Clinical and hematological responses to hydroxyurea in sicilian patients with Hb S/β-thalassemia [J].

Rigano, P ;

Rodgers, GP ;

Renda, D ;

Renda, MC ;

Aquino, A ;

Maggio, A .

HEMOGLOBIN, 2001, 25 (01) :9-17

[14] Fetal hemoglobin in sickle cell anemia: Determinants of response to hydroxyurea [J].

Steinberg, MH ;

Lu, ZH ;

Barton, FB ;

Terrin, ML ;

Charache, S ;

Dover, GJ ;

Jones, ES ;

Strayhorn, D ;

Rosse, W ;

Phillips, G ;

Peace, D ;

JohnsonTelfair, A ;

Milner, P ;

Kutlar, A ;

Tracy, A ;

Ballas, SK ;

Allen, GE ;

Moshang, J ;

Scott, B ;

Anderson, A ;

Sabahi, V ;

Pegelow, C ;

Temple, D ;

Case, E ;

Harrell, R ;

Childerie, S ;

Embury, S ;

Schmidt, B ;

Davies, D ;

Koshy, M ;

TalischyZahed, N ;

Dorn, L ;

Pendarvis, G ;

McGee, M ;

Telfer, M ;

Davis, A ;

Castro, H ;

Finke, E ;

Perlin, E ;

Siteman, J ;

Gascon, P ;

diPaolo, P ;

Gargiulo, S ;

Eckman, J ;

Bailey, JH ;

Platt, A ;

Waller, PL ;

Ramirez, G ;

Knors, V ;

Hernandez, S .

BLOOD, 1997, 89 (03) :1078-1088

[15] A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia [J].

Wang, WC ;

Wynn, LW ;

Rogers, ZR ;

Scott, JP ;

Lane, PA ;

Ware, RE .

JOURNAL OF PEDIATRICS, 2001, 139 (06) :790-796

[16] Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy [J].

Ware, RE ;

Eggleston, B ;

Redding-Lallinger, R ;

Wang, WC ;

Smith-Whitley, K ;

Daeschner, C ;

Gee, B ;

Styles, LA ;

Helms, RW ;

Kinney, TR ;

Ohene-Frempong, K .

BLOOD, 2002, 99 (01) :10-14

[17] Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea [J].

Wilson, S .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (11) :925-926

← 1 2 →